Pre-Clinical Investigation Laboratory-Breast Cancer

The Pre-clinical investigation laboratory (LIP) has 25 years of experience in developing patient-derived xenografts of a wide range of cancers including breast, colon, lung, ovary, uveal melanoma, retinoblastoma, Head and Neck cancers.

The Pre-clinical investigation laboratory is developing the next generation of PDX models, from drug-resistant tumors, metastatic cancer to humanized models. LIP services include: 
• Preclinical pharmacology & pharmacodynamics of anti-cancer drugs
• Identification of predictive biomarkers of response and resistance to anti-cancer agents
• Collaboration with many national and European academics & pharmaceutical companies 
Read more
We have established a collection of PDX from primary and metastatic breast tumors, coupled with molecular annotation including cancer panel targeted sequencing as well as transcriptomic and proteomic profiles. 


The Pre-clinical investigation laboratory is a member of the EurOPDX Consortium. EurOPDX is supported by the European Union's Horizon 2020 research and innovation program under the grant agreement No. 731105 EDIReX

You are running an old browser version. We recommend updating your browser to its latest version.

More info